Related Experiment Video
Updated: Aug 16, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
FLT3 antibody-based therapeutics for leukemia therapy
1ImClone Systems Incorporated, New York, NY 10014, USA. Yiwen.li@imclone.com
International Journal of Hematology
|September 9, 2005
Summary
Antibodies targeting FLT3 show promise for treating human leukemia. This review covers antibody therapeutics, focusing on anti-FLT3 agents for hematologic malignancies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Antibody therapeutics offer high specificity for targeted cancer treatment.
- Clinical successes have increased development of antibody-based cancer therapies.
- Antibodies against FMS-like tyrosine kinase 3 (FLT3) are emerging as a key strategy.
Purpose of the Study:
- To review antibody-based cancer therapeutics.
- To focus on the generation, development, and therapeutic potential of anti-FLT3 antibodies.
- To discuss their application in human hematologic malignancies.
Main Methods:
- Literature review of antibody therapeutics.
- Focus on mechanisms of action for antibody-based agents.
- Analysis of recent progress in anti-FLT3 antibody development.
Main Results:
- Antibodies are a unique therapeutic class due to antigen specificity.
- Anti-FLT3 antibodies present a promising avenue for leukemia treatment.
- Further development is ongoing for these agents in hematologic cancers.
Conclusions:
- Antibody therapeutics, particularly anti-FLT3, hold significant potential for treating leukemia.
- Continued research into anti-FLT3 antibodies could lead to new treatments for hematologic malignancies.
- The specificity of antibodies makes them valuable tools in cancer therapy.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...